Adenoid cystic carcinoma of the breast in the United States (1977 to 2006): a population-based cohort study by Ghabach, Bassam et al.
RESEARCH ARTICLE Open Access
Adenoid cystic carcinoma of the breast in the
United States (1977 to 2006): a population-based
cohort study
Bassam Ghabach
1,2*, William F Anderson
3, Rochelle E Curtis
3, Mark M Huycke
1,2, Jackie A Lavigne
3,
Graça M Dores
1,3
Abstract
Introduction: Adenoid cystic carcinoma of the breast (breast-ACC) is a rare and special type of basal-like tumor for
which scant population-based descriptive data exist. We sought to provide new population-based information on
breast-ACC incidence, relative survival, and associated cancer risk in the United States.
Methods: Using data from the Surveillance, Epidemiology and End Results Program, we calculated age-adjusted
incidence rates (IRs), IR ratios (IRRs), and relative survival for breast-ACC, and standardized incidence ratios (SIRs) for
other cancers.
Results: Overall 338 women (IR = 0.92/1 million person-years) were diagnosed with breast-ACC during 1977 to
2006. Blacks had 39% lower IRs than Whites (IRR = 0.61, 95% confidence interval = 0.37 to 0.96), and IRs remained
constant over the 30-year period. Ninety-five percent of cases presented with localized stage (n = 320; IR = 0.87),
and the highest IRs were observed for estrogen receptor (ER)-negative/progesterone receptor (PR)-negative tumors
(IR = 0.56). Like other typically ER-negative tumors, age-specific IRs increased until midlife and then plateaued. Five-
year, 10-year, and 15-year relative survival was 98.1%, 94.9%, and 91.4%, respectively. The risk of female breast
cancer was not increased following (SIR = 0.89, 95% confidence interval = 0.43 to 1.64) or preceding (SIR = 0.71,
95% confidence interval = 0.28 to 1.46) breast-ACC. Similarly, no association was observed for breast-ACC and risk
of all other cancers combined, solid tumors, or lymphohematopoietic malignancies.
Conclusions: Breast-ACC among women is characterized by ER-negative/PR-negative expression, rare regional
lymph node involvement, a favorable prognosis with excellent survival, and absence of associated cancers. These
findings reinforce the importance of tailored treatments for breast-ACC and lend credence to the apparent
heterogeneity of basal-like breast cancers.
Introduction
Adenoid cystic carcinoma (ACC) of the breast (breast-
ACC) is a rare basal-like breast cancer [1-3]. Previously
termed cylindroma, ACC was initially described by Bill-
roth in 1856 [4] - with the first description of breast-
ACC credited to Geschickter in 1945 [5]. The term
cylindroma is now used exclusively to describe benign
appendageal tumors of the skin. The morphologic
appearance of breast-ACC is similar to ACC occurring
at other organ sites, including the salivary gland, lung,
and skin [1,6-13]. The diagnostic criteria for breast-ACC
i n c l u d e st h ep r e s e n c eo fab i phasic cellular pattern of
myoepithelial and epithelial cells (basaloid and ductal)
[1,6,14,15]. True to the molecular signature of basal-like
tumors [2,3,16], breast-ACC is often estrogen receptor
(ER)-negative and progesterone receptor (PR)-negative
[17-20] and does not express HER-2-neu [18,20,21].
Clinical studies suggest that breast-ACC is associated
with a favorable survival [22-25], thus belying the
expected poor prognosis suggested by the absence of
hormone receptor expression.
While the epidemiology of other special breast cancer
types, including medullary and papillary carcinomas, has
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information on breast-ACC is derived from case reports
and clinical series - with the largest series reporting
fewer than 40 cases [22-24,27] - including one popula-
tion-based study [28]. Reports of breast-ACC have origi-
nated from Europe, North America, Australia, and Asia,
with the majority describing a female predominance
[14,21,23,24,27-39]. Information on race and ethnicity is
sparse, and it is uncertain whether a racial predilection
exists for breast-ACC [35,40]. In addition, synchronous
and metachronous breast tumors and nonbreast tumors
occurring with breast-ACC have been described
[14,23-25,27,28,32,41,42], but the risk of associated can-
cers has not been quantified. To gain insight into the
epidemiologic features of breast-ACC, we undertook a
population-based study in the Surveillance, Epidemiol-
ogy and End Results (SEER) Program to provide new
information on incidence, relative survival, and asso-
ciated cancer risk.
Materials and methods
We utilized data from nine cancer registry areas of the
S E E RP r o g r a m( S E E R - 9 )t h a tr e p r e s e n ta p p r o x i m a t e l y
10% of the population in the United States. SEER-9
includes the states of Connecticut, Hawaii, Iowa, New
Mexico, and Utah and the areas of Detroit in Michigan,
San Francisco in California, Atlanta in Georgia, and
Seattle (Puget Sound) in Washington. These nine areas
include a racially diverse population representing
approximately 9% Whites, 9% Blacks, 13% American
Indians/Alaskan Natives, 19% Asians, 46% Native
Hawaiians/Pacific Islanders, and 8% of other races in the
United States [43].
The SEER Program classifies histology and topography
information according to the third edition of the Inter-
national Classification of Diseases for Oncology [44]. We
included all cases of microscopically confirmed, invasive
(behavior code of/3) ACC (M8200) of the breast (C500-
509) diagnosed during 1977 to 2006.
Incidence
We calculated incidence rates (IRs), IR ratios (IRRs), and
95% confidence intervals (CIs) using the Rate Session in
the SEER*Stat software (version 6.5.2; Surveillance
Research Program, National Cancer Institute, Bethesda,
Maryland, USA) [3]. Incidence rates were age-adjusted
to the 2000 US standard population and are expressed
per 1 million person-years.
Among females diagnosed with breast-ACC during
1977 to 2006, we assessed IRs according to race (White,
Black, other/unspecified), calendar period (1977 to 1986,
1987 to 1996, 1997 to 2006), age (<50, ≥50 years), later-
ality (right, left, bilateral, unspecified), quadrant (upper
inner quadrant (C50.2), lower inner quadrant (C50.3),
lower outer quadrant (C50.5), upper outer quadrant
(C50.4, C50.6), central/nipple (C50.0-50.1), overlapping
(C50.8), not specified (C50.9)), SEER stage (localized,
r e g i o n a l ,d i s t a n t ,u n s t a g e d ) ,a n dg r a d e( l o wg r a d e ,
including grades I and II; high grade, including grade III
and IV; unknown). Localized stage includes tumors con-
fined to breast tissue or fat, including nipple and areola
(but not skin); regional stage includes tumors that
directly extend to local structures (for example, skin,
chest wall, muscle, ribs) and/or local lymph nodes (LNs)
(for example, axillary, internal mammary); and distant
stage includes tumors that have spread to distant organs
(for example, bone, lung, adrenal) or distant LNs (for
example, cervical, supraclavicular, contralateral axillary/
internal mammary). Excluding inflammatory carcinoma,
the major change in SEER staging over the study period
was that beginning in 2000 infraclavicular LN involve-
ment was considered regional stage whereas it had pre-
viously been classified as distant stage.
Information on tumor size and regional LN involve-
ment was not collected in the SEER Program until 1988,
and data on ER and PR status did not become available
until 1990. We therefore limited analyses of tumor size
(≤2 cm, >2 cm, unspecified) and LN status (negative,
positive, unspecified) to cases diagnosed during 1988 to
2006, and limited analyses of ER (positive, negative,
other/unspecified) and PR (positive, negative, other/
unspecified) to breast-ACC diagnosed during 1990 to
2006. Treatment information in the SEER Program is
limited to that received with the initial cancer diagnosis
(surgery, radiation therapy), and data on subsequent
therapy are not collected. Information on chemotherapy
and hormonal therapy is not available in the SEER Pub-
lic Use Database.
Age-specific IRs were calculated according to eight age
groups (<15 years, 15 to 24 years, 25 to 34 years, 35 to
44 years, 45 to 54 years, 55 to 64 years, 65 to 74 years,
≥75 years) and depicted on a log-linear scale as pre-
viously described [45]. For the purpose of comparison,
we calculated age-specific IRs for other microscopically
confirmed special types of female breast cancer, includ-
ing lobular (M8520), mucinous (M8480), tubular
(M8211), medullary (M8510), and papillary (M8050,
8260, 8503) carcinomas. According to the SEER Pro-
gram convention, incidence rates were not calculated
for fewer than 16 cases [46].
Multiple primary cancers
We assessed the risk of subsequent cancer among 2-
month survivors of breast-ACC and the risk of subse-
quent breast-ACC among more than 1.2 million
2-month survivors of all cancers diagnosed between 1
January 1977 and 31 December 2006 using the standar-
dized incidence ratio (SIR) session in the SEER*Stat
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ited to females because of the rare occurrence of breast-
ACC among males. SIRs or observed-to-expected
number of subsequent cancers and exact 95% CIs were
calculated by compiling person-years of observation
according to age, gender, race, and calendar period
beginning 2 months after the diagnosis of cancer to the
study end date, date of death, or date of last known fol-
low-up, whichever occurred first. The expected number
of subsequent cancers was estimated by calculating can-
cer IRs according to gender, race, 5-year age groups,
and 5-year calendar periods and then multiplying by the
person-years at risk.
Survival
Using the SEER*Stat Survival Session, we estimated 5-year,
10-year, and 15-year relative survival of breast-ACC and
95% CIs using the actuarial method. We included all cases
of microscopically confirmed, invasive breast-ACC among
women with known age who were diagnosed in SEER-9
during 1977 to 2005 and were actively followed for vital
status through 2006. We excluded cases diagnosed among
individuals with second or later primary cancers (n = 34).
There were no cases of breast-ACC diagnosed by death
certificate or autopsy, with invalid vital status or dates, or
with unknown survival time. Survival rates were not calcu-
lated for fewer than 25 cases [46].
Results
Overall 338 women (IR = 0.92/1 million person-years)
(Table 1) and five men were diagnosed with breast-ACC
during 1977 to 2006. Owing to the small number of cases
among men, further analyses were restricted to women.
Mean and median ages at diagnosis were 63 years and 62
years (range 33 to 97 years), respectively, among women.
The majority of cases were diagnosed among White
women, and Black women had 39% significantly lower
IRs than Whites (IRR = 0.61, 95% CI = 0.37 to 0.96). IRs
of breast-ACC did not change appreciably over the 30-
year study period. Women aged 50 years or older had an
11-fold higher incidence of breast-ACC than younger
women (IRR = 11.02, 95% CI = 8.31 to 14.87). Rates did
not differ by left-sided or right-sided laterality (IRR =
1.06, 95% CI = 0.85 to 1.32), and there were no cases of
bilateral breast-ACC. Most cancers occurred in the upper
outer quadrants, with more than 70% lower IRs for
breast-ACC occurring in each of the other quadrants.
Ninety-five percent of cases presented at localized stage
(n = 320; IR = 0.87), with regional and distant disease
reported rarely. Thirty percent of women (n =1 0 2 )w e r e
treated with radiation as part of initial therapy for breast-
ACC, whereas the remaining 70% (n = 236) were not.
Table 1 Age-adjusted female adenoid cystic carcinoma of
the breast incidence rates and incidence rate ratios
Total
Characteristic n IR IRR 95% CI
Total 338 0.92 NA
Race
Whites 295 0.97 1.00 Reference
Blacks 20 0.59 0.61 0.37 to 0.96
Other/unspecified 23 ~ ~ ~
Calendar period
1977 to 1986 79 0.78 1.00 Reference
1987 to 1996 121 1.02 1.30 0.97 to 1.76
1997 to 2006 138 0.96 1.23 0.93 to 1.65
Age
<50 years 59 0.25 1.00 Reference
≥50 years 279 2.70 11.02 8.31 to 14.87
Laterality
Right 164 0.45 1.00 Reference
Left 173 0.47 1.06 0.85 to 1.32
Not specified 1 ~ ~ ~
Site
Upper outer quadrant 105 0.29 1.00 Reference
Upper inner quadrant 29 0.08 0.28 0.18 to 0.43
Lower outer quadrant 23 0.06 0.22 0.13 to 0.35
Lower inner quadrant 14 ~ ~ ~
Nipple/central 28 0.08 0.27 0.17 to 0.41
Overlapping 89 0.24 0.83 0.62 to 1.11
Not specified 50 0.14 0.47 0.33 to 0.67
Stage
Localized 320 0.87 1.00 Reference
Regional 14 ~ ~ ~
Distant 1 ~ ~ ~
Unstaged 3 ~ ~ ~
LN and size
a
LN negative, ≤2 cm 126 0.50 1.00 Reference
LN negative, >2 cm 67 0.26 0.52 0.38 to 0.71
LN positive, ≤2c m 2 ~ ~ ~
LN positive, >2 cm 3 ~ ~ ~
Other/not specified 46 0.18 0.36 0.25 to 0.51
Hormone receptors
b
ER-negative/PR-negative 128 0.56 1.00 Reference
ER-negative/PR-positive 6 ~ ~ ~
ER-positive/PR-positive 21 0.09 0.16 0.10 to 0.25
ER-positive/PR-negative 12 ~ ~ ~
Other/not specified 55 0.24 0.42 0.30 to 0.59
Data from the nine cancer registry areas of the Surveillance, Epidemiology
and End Results Program, 1977 to 2006. Incidence rates are age-adjusted to
the 2000 US standard population and are expressed per 1 million person-
years. Incidence rate ratios are based on unrounded rates. n, number of cases;
IR, incidence rate; IRR, incidence rate ratio; CI, confidence interval; NA, not
applicable; ~, IRs and IRRs not calculated for fewer than 16 cases or other/
unspecified race; LN, regional lymph nodes; ER, estrogen receptor; PR,
progesterone receptor.
aLimited to cases with localized/regional stage
diagnosed in 1988 or later.
bLimited to cases diagnosed in 1990 or later.
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diagnosed in 1988 or later was 2.1 cm and 1.8 cm
(range 0.1 to 16.0 cm; n = 229), respectively. The tumor
size was unspecified for 7% of women (n = 18). Most
women with localized and regional stage breast-ACC
had uninvolved LN, with 48% significantly lower inci-
dence of tumors >2 cm compared with smaller tumors
(IRR = 0.52, 95% CI = 0.38 to 0.71). Grade was not spe-
cified for 61% of cases (n = 207), thereby limiting
further analysis. The majority of female breast-ACC
were ER-negative/PR-negative (IR = 0.56, n = 128).
Breast-ACC age-specific IRs increased prominently
beginning at ages 35 to 44 years, with a less marked rise
in incidence at older ages and an apparent plateau
beginning at ages 55 to 64 years (Figure 1). A similar
pattern was noted for medullary breast cancer (n =
5,973, IR = 16.62), with the exception that IRs decreased
more prominently among the oldest age group (≥75
years). In contrast, papillary (n = 2,902, IR = 7.72) and
mucinous (n = 10,404, IR = 27.73) female breast cancer
IRs increased exponentially with advancing age. Lobular
(n = 34,048, IR = 92.52) and tubular (n = 5,833, IR =
16.07) carcinomas were characterized by an intermediate
Figure 1 Age-specific incidence rates of special types of female breast carcinomas. Data from the nine cancer registry areas of the
Surveillance, Epidemiology and End Results Program, 1977 to 2006.
Table 2 Standardized incidence ratios of subsequent
cancer among 2-month female survivors of first primary
breast-ACC
Subsequent cancer
a Obs. SIR 95% CI
All cancers, excluding nonmelanoma skin 40 1.01 0.72 to 1.38
All solid cancers 33 0.94 0.65 to 1.32
Colon and rectum 8 1.43 0.62 to 2.81
Lung and bronchus 7 1.24 0.50 to 2.55
Female breast 10 0.89 0.43 to 1.64
Uterine corpus 3 1.27 0.26 to 3.72
All lymphohematopoietic cancers 6 1.86 0.68 to 4.05
Non-Hodgkin lymphoma 4 2.44 0.66 to 6.24
Acute myeloid leukemia 2 7.24 0.88 to 26.16
Data from the nine cancer registry areas of the Surveillance, Epidemiology
and End Results Program, 1977 to 2006. Breast-ACC, adenoid cystic carcinoma
of the breast; Obs., observed number of subsequent cancers; SIR, standardized
incidence ratio; CI, confidence interval.
aLimited to cancer sites with >1 case
diagnosed among 300 2-month survivors (2,986 female-years; mean follow-up
9.95 years) of first primary breast-ACC. There was one individual with
miscellaneous cancer that is not included in the all solid cancers or all
lymphohematopoietic cancers categories.
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midlife, followed by a persistent but less steep rise in
incidence at older ages.
The overall risk of second-order or higher-order can-
cers following breast-ACC among females was not
increased (SIR = 1.01, 95% CI = 0.72 to 1.38, observed
number of subsequent cancers = 40) (Table 2). Subse-
quent risk of all solid tumors did not differ from that
expected in the general population (SIR = 0.94, 95% CI
= 0.65 to 1.32, observed number of subsequent cancers
= 33), and similarly the risk of any breast cancer was
not increased (SIR = 0.89, 95% CI = 0.43 to 1.64,
observed number of subsequent cancers = 10). Based on
a small number of cases, the risk of lymphohematopoie-
tic malignancies was nonsignificantly increased after
breast-ACC (SIR = 1.86, 95% CI = 0.68 to 4.05, observed
number of subsequent cancers = 6). No cancers
occurred significantly below expectation.
The risk of developing a subsequent breast-ACC fol-
lowing all first cancers and all solid tumors did not dif-
fer from that expected in the general population (SIR =
0.86 and 0.91, respectively), and no cases of breast-ACC
were reported following lymphohematopoietic malignan-
cies (Table 3). Following a diagnosis of any first primary
breast cancer, risk of breast-ACC was not elevated
beyond expectation (SIR = 0.71, 95% CI = 0.28 to 1.46).
Colorectal and urinary bladder cancers as well as mela-
noma were associated with nonsignificantly elevated
risks of subsequent breast-ACC.
The overall 5-year relative survival of breast-ACC was
98.1% with 96 to 97% relative survival observed across
all calendar periods studied (Table 4). Five-year relative
survival was excellent among women aged <50 years
(94.4%) and ≥50 years (99.0%). Among women diag-
n o s e di n1 9 8 8o rl a t e rw i t h o u tL Ni n v o l v e m e n t ,5 - y e a r
relative survival was 99.1% (n = 100) and 89.7% (n = 56)
among those with tumors ≤2 cm and >2 cm tumors,
respectively (data not shown). Overall 10-year and 15-
year relative survival exceeded 90%. Women aged <50
and ≥50 years had similar 10-year relative survival
(94.4%), but slightly lower relative survival was noted at
15 years for older women (88.9%) than for younger
women (94.3%).
Discussion
To date the largest breast-ACC studies
[14,22-25,27,30,32,36,41], including one population-
based study [28], have each included fewer than 40
cases, with some studies including cases diagnosed over
a ≥40-year time period [23,24,30]. With more than 300
incident cases of breast-ACC occurring over a 30-year
period, our study is the largest reported to date and is
the first to describe incidence, survival, and associated
cancers. New population-based information includes the
predominance of breast-ACC among females and
Whites, with the majority of tumors characterized by
ER-negative/PR-negative hormone receptor status, loca-
lized stage, and absence of regional LN involvement.
Breast-ACC IRs remained stable over the 30 years of
study, and relative survival was excellent. In contrast to
the 60% significantly increased risk of contralateral
breast cancer following an initial female breast cancer
reported in a previous SEER-based study [47], we did
not find an increased risk for breast cancer preceding or
following breast-ACC. Similarly, no increased risk was
observed for all cancers combined or all solid tumors
occurring in association with breast-ACC.
Breast-ACC is a rare malignancy, with approximately
one case occurring per 1 million female-years. Based on
a substantially larger number of cases, we found a simi-
lar mean age at diagnosis as previously reported among
14 histologically confirmed breast-ACC cases diagnosed
during 1952 to 1982 in the Connecticut Tumor Registry
(mean age 64 years) [28]. Some series have similarly
Table 3 Standardized incidence ratios of subsequent breast-ACC among two-month female survivors of other first
primary cancers
First primary cancer Subsequent breast-ACC
Site n Mean person-years Obs. SIR 95% CI
All, excluding nonmelanoma skin 1,239,815 7.04 20 0.86 0.52 to 1.33
All solid 1,122,676 7.24 20 0.91 0.56 to 1.41
Colon and rectum 151,082 6.42 5 1.70 0.55 to 3.96
Melanoma, skin 43,155 9.93 2 2.19 0.27 to 7.91
Female breast 410,448 8.58 7 0.71 0.28 to 1.46
Uterine corpus 90,916 10.48 2 0.69 0.08 to 2.48
Urinary bladder 29,309 7.41 2 2.99 0.36 to 10.81
All lymphohematopoietic cancers 96,222 5.80 0 [E = 1.24]
Data from the nine cancer registry areas of the Surveillance, Epidemiology and End Results Program, 1977 to 2006. Except for the general category of all
lymphohematopoietic cancers, the table is limited to cancers with >1 case of subsequent breast-ACC. Breast-ACC, adenoid cystic carcinoma of the breast; n,
number of first primary cancers; Obs., observed number of subsequent breast-ACC; SIR, standardized incidence ratio; CI, confidence interval; E, expected number
of subsequent breast-ACC.
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sis [12,22,23,36,42], whereas others have described ages
that are nearly one decade younger [17,20,21,24,25,
32,34,41]. Breast-ACC often presents with a palpable
[15,17,23-25,32,41] and tender [14,15,23,24,37,48,49]
mass, which is variably detected on mammography and
ultrasound [25,35-37,48,50-52]. Similar to what has been
suggested in the literature, we found that tumor size
varies widely. Mean tumor sizes of 1.8 to 3.7 cm have
been described [12,20,21,23,25,32,42], and not uncom-
monly the breast mass is noted to have been present
several years prior to diagnosis [8,25,30,36,41,49,50,53].
Clinical series report a predominance of centrally
located tumors [14,15,19,25,32,51,52,54], nearly equal
frequencies of central and upper outer quadrant tumors
[15,27,42], or - akin to findings in the SEER Program -
tumors occurring primarily in the upper outer quadrant
[8,28,34].
Supporting findings in previous reports
[15,17-21,27,29,31,35-38,48,50,52,54-57], the majority of
breast-ACC in the SEER Program was ER-negative/PR-
negative; however, hormone receptor-positive tumors
have also been described in a minority of cases
[22,23,25,32,34,42,58]. Although information on HER-2-
neu is not available in the SEER Program, other series
have uniformly reported HER-2-neu-negative status in
breast-ACC [18,20,21,23,31,34,37,38,42,50,52,55,56]. Like
HER-2-neu negativity, c-kit expression is typically a
poor prognostic feature that also characterizes breast-
ACC [18,21,29,31,34] as well as medullary breast cancer,
another basal-like breast cancer [59,60]. In contrast to
what might be expected with ER-negative, PR-negative,
HER-2-neu-negative (triple-negative) breast cancers, the
majority of cases of breast-ACC in the SEER Program
rarely involved regional LN and most were associated
with excellent survival. These findings support clinical
reports that largely [12,20-25,29,31,32,34-38,41,42,48,50-
52,55,56], but not exclusively [21-24,34,42,49], describe
absence of LN involvement and excellent survival
[22,24,25]. Metastatic breast-ACC has been rarely
reported at initial diagnosis [22], and only one case was
observed in the SEER Program over a 30-year period.
The mainstay of therapy for breast-ACC has been sur-
gical excision with or without local radiotherapy, with
infrequent use of chemotherapy and hormonal therapy
[21-24,38,41,42,52,55]. Single or multiple recurrences
may occur years after initial diagnosis [8,11,13,20,21,23,
27,32,33,39,40,49], and a similar pattern of recurrence
has been observed for other triple-negative breast
cancers [61].
Similar to the IR pattern previously described for
medullary breast cancer, a predominantly ER-negative
tumor [26], we found an early-onset incidence pattern
for breast-ACC - a rapid rise in incidence at young ages
with falling or flattening incidence rates after midlife.
Early-onset breast cancer incidence patterns suggest a
prominent etiologic role for hormonal influences that
occur early in reproductive life [26]. This is, at least in
part, a plausible explanation for the markedly higher
incidence of breast cancer among females (IR = 132.5/
100,000 woman-years) than males (IR = 0.2/100,000
man-years) [62]. In contrast, late-onset incidence pat-
terns - as exemplified by papillary and mucinous breast
cancers, typically ER-positive cancers of presumed lumi-
nal origin - are characterized by a progressive rise in
incidence with advancing age, possibly due to lifelong
carcinogenic events and/or exposures [16,26]. Interest-
ingly, papillary carcinomas are among the most common
special breast cancer types in males, whereas medullary
carcinomas are among the least common [62]. Lobular
and tubular breast cancers have age-specific curves that
are intermediate between early-onset and late-onset pat-
terns and are postulated to represent a bimodal, mixed
population of early-onset and late-onset cancers [26].
The incidence of breast-ACC remained stable during
the 30-year study period with no notable rise after the
widespread use of mammography beginning in the 1980s.
Systematic mammographic screening in the United States
has largely resulted in an increase in breast cancer IRs
among women ≥50 years of age and in a shift to older
age at diagnosis [63,64]. Since breast-ACC is character-
ized by an early-onset age pattern, this may explain, at
least in part, why the introduction of mammographic
screening has not apparently influenced temporal pat-
terns. In addition, breast-ACC has been reported to be
variably detected on mammogram [25,35-37,48,50-52],
Table 4 Relative survival among females diagnosed with
adenoid cystic carcinoma of the breast
5-year RS 10-year RS 15-year RS
Characteristic n % 95% CI % 95% CI % 95% CI
Total 285 98.1 79.9 to
99.8
94.9 78.9 to
98.8
91.4 75.0 to
97.2
Calendar period
1977 to
1986
74 96.8 63.3 to
99.8
95.2 67.1 to
99.4
95.2 67.1 to
99.4
1987 to
1996
109 97.2 81.4 to
99.6
91.0 69.7 to
97.6
85.0 60.7 to
94.9
1997 to
2005
102 96.0 68.5 to
99.6
~~ ~~
Age
<50 years 52 94.4 80.3 to
98.5
94.4 80.3 to
98.5
94.3 69.4 to
99.1
≥50 years 233 99.0 6.6 to
100
94.4 72.8 to
99.0
88.9 68.9 to
96.3
Data from the nine cancer registry areas of the Surveillance, Epidemiology
and End Results Program, 1977 to 2006. Relative survival is based on cases
diagnosed during 1977 to 2005 and followed through 2006. n, number of
cases; RS, relative survival; CI, confidence interval; ~, insufficient follow-up to
calculate survival.
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with the introduction of mammographic screening. Tem-
poral patterns should also be interpreted in the context
of the rarity of breast-ACC, such that the relatively small
numbers of cases may have limited our ability to detect
significant changes in IRs.
Breast-ACC has been described worldwide but race is
rarely specified among reports in the literature [35,40].
We found a significantly lower incidence of breast-ACC
among Blacks than Whites, which contrasts with the
twofold higher incidence of medullary breast cancer
described among Blacks compared with Whites [3,26].
These findings suggest that racial differences in suscept-
ibility exist within subtypes of basal-like breast cancers.
Synchronous and metachronous in situ and invasive
carcinomas have been described in the ipsilateral breast
as well as in the contralateral breast in women with
breast-ACC [12,14,23-25,31,32,36,42]. Notably, when
breast-ACC occurs in conjunction with breast cancer of
another histologic subtype, the prognosis is that of the
other subtype [7,12,41]. Nonbreast cancers - including
lymphoma [24], ocular melanoma [25], and cancers of
the ovary [28], endometrium [24], supraglottis [24], kid-
ney [24], lung [27], and skin [42] - have been described
among patients with breast-ACC. Based on 18 cases of
breast-ACC, Millar and colleagues found a subsequent
cancer rate of 13%, 19%, and 26% at 5 years, 10 years,
and 15 years, respectively [24]. We did not find a signifi-
cantly increased risk of all cancers combined, or cancers
of the breast or other sites prior to or following breast-
ACC when rates were compared with the US general
population.
The strengths of our study include the relatively large
number of breast-ACC in a population-based setting,
which avoids biases inherent to clinical series. Despite
the size of our study, however, one limitation is that too
few men were diagnosed with breast-ACC to allow cal-
culation of IRs or survival rates. While SEER-9 repre-
sents approximately 10% of the US population, our
findings may not be generalizable to women in the
entire country nor to other non-US populations, parti-
cularly if the racial composition differs. Although we
included only microscopically confirmed cases, we did
not undertake a pathology review and we cannot
exclude the possibility of misclassified cribriform carci-
noma, benign collagenous spherulosis, or other entities
included in the differential diagnosis of breast-ACC
[7,12,15,20,41,42,65,66]. Reassuring, however, is that a
pathology review of breast-ACC undertaken in the Con-
necticut Tumor Registry during 1952 to 1982 found
79% accuracy for cases diagnosed after 1974 in contrast
to 23% accuracy for cases diagnosed prior to 1974 [28].
Another limitation of our study is that information on
hormone receptor status was derived from numerous
laboratories using different measurement techniques
with varying definitions of positive receptor status.
Nevertheless, substantial agreement has been reported
between centralized laboratory and SEER registry classi-
fication for ER-positive/PR-positive and ER-negative/PR-
negative breast cancer subtypes [67]. Without a formal
pathology review, it is not possible to determine whether
the ER-positive and PR-positive breast-ACC cases we
observed are misclassified by histology and/or receptor
status or represent a true variant of breast-ACC. Nota-
bly, hormone receptor-positive breast-ACC has been
reported in several clinical series [22,23,25,32,34,42,58].
We were also unable to assess breast-ACC recurrence
rates because the SEER Program does not collect infor-
mation on recurrent disease. Finally, despite the rela-
tively large size of our study, it is possible that
significant cancer associations may have gone unde-
tected because of the small absolute number of breast-
ACC cases.
Conclusions
The present study is the largest of breast-ACC reported
to date and the first to describe population-based inci-
dence, survival, and associated cancer patterns. Support-
ing previous descriptions from clinical series, we found
a predominance of breast-ACC among women charac-
terized by ER-negative/PR-negative hormone receptor
status, rare regional LN involvement, and excellent sur-
vival. An increased risk of breast cancer or other cancers
overall was not observed in association with breast-
ACC; however, larger studies will be needed to confirm
our findings. Awareness of the favorable clinical beha-
vior of breast-ACC is important, and these findings
emphasize the need for clinicians to balance the risks
and benefits of cytotoxic therapy given the excellent
long-term survival. Future studies may consider pooling
cases of breast-ACC to develop additional insight into
the molecular pathogenesis, etiology, and best treatment
approaches of this rare basal-like breast cancer.
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